according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 4164051-00017 Date of first issue: 17.04.2019 4.11

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Oxytetracycline / Diclofenac Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Veterinary product

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company **MSD**

Kilsheelan

Clonmel Tipperary, IE

Telephone 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eve irritation, Category 2 H319: Causes serious eye irritation. Skin sensitisation, Category 1 H317: May cause an allergic skin reaction.

Reproductive toxicity, Category 1A H360FD: May damage fertility. May damage the

unborn child.

Specific target organ toxicity - repeated

H373: May cause damage to organs through pro-

exposure, Category 2

longed or repeated exposure.

Short-term (acute) aquatic hazard, Cate-

H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Cat-

H410: Very toxic to aquatic life with long lasting

egory 1

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Hazard pictograms



!



Signal word : Danger

Hazard statements : H317 May cause an allergic skin reaction.

H319 Causes serious eye irritation.

H360FD May damage fertility. May damage the unborn

child.

H373 May cause damage to organs through prolonged

or repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P333 + P313 If skin irritation or rash occurs: Get medical

advice/ attention.

P391 Collect spillage.

Hazardous components which must be listed on the label:

oxytetracycline

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Componente			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

	Index-No. Registration number		
2-Pyrrolidone	616-45-5 210-483-1	Eye Irrit. 2; H319 Repr. 1B; H360FD	>= 50 - < 70
		specific concentration limit Repr. 1B; H360FD > 3 %	
oxytetracycline	79-57-2 201-212-8	Skin Sens. 1A; H317 Repr. 1A; H360D Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 20 - < 25
		M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	
Sodium [2-[(2,6-dichloro-phenyl]acetate	15307-79-6 239-346-4	Acute Tox. 3; H301 Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate) Aquatic Chronic 2; H411	>= 1 - < 2.5
Sodium hydroxymethanesulphinate	6035-47-8	Muta. 2; H341 Repr. 2; H361d	>= 0.1 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause an allergic skin reaction.

Causes serious eye irritation.

May damage fertility. May damage the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Chlorine compounds Nitrogen oxides (NOx)

Sodium oxides

Carbon oxides

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions :

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

•				
Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
oxytetracycline	79-57-2	TWA	500 μg/m3 (OEB 2)	Internal
	Further information: DSEN			
		Wipe limit	100 μg/100 cm ²	Internal
Propylene glycol	57-55-6	OELV - 8 hrs	10 mg/m3	IE OEL

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

		(TWA) (particles)		
		OELV - 8 hrs (TWA) (total (va- pour and parti- cles))	150 ppm 470 mg/m3	IE OEL
Magnesium oxide	1309-48-4	OELV - 8 hrs (TWA) (Fumes)	5 mg/m3	IE OEL
		OELV - 8 hrs (TWA) (Respira- ble dust)	4 mg/m3	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m3	IE OEL
		OELV - 15 min (STEL) (Fumes)	10 mg/m3	IE OEL
Sodium [2-[(2,6-dichloro-phe-nyl)amino]phenyl]a cetate	15307-79-6	TWA	100 μg/m3 (OEB 2)	Internal
	Further information: Skin			

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Pyrrolidone	Workers	Inhalation	Long-term systemic effects	57.8 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	277 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	17.1 mg/m3
	Consumers	Skin contact	Long-term systemic effects	6 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	167 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5.2 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	33.3 mg/kg bw/day
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

0 1 -1	F. 'a (a) O	1/-1 -
Substance name	Environmental Compartment	Value
2-Pyrrolidone	Fresh water	0.5 mg/l
	Freshwater - intermittent	0.5 mg/l
	Marine water	0.05 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	0.4205 mg/kg dry
		weight (d.w.)
	Soil	0.0612 mg/kg dry
		weight (d.w.)
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg dry
		weight (d.w.)
	Marine sediment	57.2 mg/kg dry
		weight (d.w.)
	Soil	50 mg/kg dry
		weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection

Work uniform or laboratory coat.

Respiratory protection : If a

If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : brown, Greenish yellow

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Odour : characteristic

Odour Threshold : No data available

Melting point/freezing point : -33 °C

Initial boiling point and boiling

range

100.5 °C

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, dynamic : 50.3 - 50.7 mPa.s (25 °C)

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : 1.15 - 1.19 (25 °C)

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.11 28.09.2024 4164051-00017 Date of first issue: 17.04.2019

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Ingestion
Eye contact

_,`

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

2-Pyrrolidone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Method: OECD Test Guideline 401

Assessment: The substance or mixture has no acute oral tox-

icity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

oxytetracycline:

Acute oral toxicity : LD50 (Rat): 4,800 mg/kg

LD50 (Mouse): 2,240 mg/kg

Remarks: Evidence of phototoxicity was observed

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 4,840 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 3,500 mg/kg Application Route: Subcutaneous

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Acute oral toxicity : LD50 (Rat): 55 - 240 mg/kg

LD50 (Mouse): 170 - 389 mg/kg

Acute toxicity (other routes of:

administration)

LD50 (Rat): 97 - 161 mg/kg

Application Route: Intravenous

LD50 (Mouse): 92 - 147 mg/kg Application Route: Intravenous

Sodium hydroxymethanesulphinate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 423

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

2-Pyrrolidone:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.11 28.09.2024 4164051-00017 Date of first issue: 17.04.2019

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

oxytetracycline:

Remarks : No data available

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : irritating

Sodium hydroxymethanesulphinate:

Species : Rat

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-Pyrrolidone:

Species : Rabbit

Result : Irritation to eyes, reversing within 7 days

oxytetracycline:

Remarks : No data available

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : Mild eye irritation

Sodium hydroxymethanesulphinate:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

2-Pyrrolidone:

Test Type : Local lymph node assay (LLNA)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Exposure routes : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Remarks : Based on data from similar materials

oxytetracycline:

Test Type : Human repeat insult patch test (HRIPT)

Result : Sensitiser

Sodium hydroxymethanesulphinate:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

2-Pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

oxytetracycline:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

Result: negative

Test Type: Mouse Lymphoma

Metabolic activation: Metabolic activation

Result: positive

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.11 28.09.2024 4164051-00017 Date of first issue: 17.04.2019

Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells

Result: equivocal

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: equivocal

Test Type: in vivo assay

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: CHO Result: negative

Sodium hydroxymethanesulphinate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Method: OECD Test Guideline 474

Result: positive

Remarks: Based on data from similar materials

Germ cell mutagenicity- As-

sessment

Positive result(s) from in vivo mammalian somatic cell muta-

genicity tests.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Carcinogenicity

Not classified based on available information.

Components:

2-Pyrrolidone:

Species : Mouse
Application Route : Ingestion
Exposure time : 18 month(s)
Result : negative

Remarks : Based on data from similar materials

oxytetracycline:

Species : Mouse
Application Route : Oral
Exposure time : 104 weeks
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 103 weeks
Result : equivocal

Target Organs : Adrenal gland, Pituitary gland

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

2-Pyrrolidone:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: positive

Remarks: Based on data from similar materials

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Effects on foetal develop-

ment

: Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: positive

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse

effects on development, based on animal experiments.

oxytetracycline:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 18 mg/kg body weight

Result: No effects on fertility, No effect on reproduction capac-

ity, No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 48 mg/kg body weight Result: Postimplantation loss., Skeletal malformations

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 1,200 mg/kg body weight Embryo-foetal toxicity: NOAEL: 1,500 mg/kg body weight

Result: No teratogenic effects

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

General Toxicity Maternal: LOAEL: 1,325 mg/kg body weight Embryo-foetal toxicity: NOAEL: 2,100 mg/kg body weight

Result: No teratogenic effects

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 41.5 mg/kg body weight Result: Postimplantation loss., No foetal abnormalities

Test Type: Embryo-foetal development

Species: Dog

Application Route: Intramuscular

Embryo-foetal toxicity: LOAEL: 20.75 mg/kg body weight Result: Skeletal and visceral variations, Postimplantation loss.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 4 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

: Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 5 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

Sodium hydroxymethanesulphinate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 414

Result: positive

Remarks: Based on data from similar materials

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.11 28.09.2024 4164051-00017 Date of first issue: 17.04.2019

Components:

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

2-Pyrrolidone:

Species : Rat NOAEL : 207

NOAEL : 207 mg/kg Application Route : Ingestion Exposure time : 3 Months

Method : OECD Test Guideline 408

oxytetracycline:

Species : Rat
LOAEL : 198 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Mouse LOAEL : 7,990 mg/kg Application Route : Oral

Exposure time : 13 Weeks
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 125 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Testis

Remarks : Significant toxicity observed in testing

Species : Rat

NOAEL : 40 mg/kg

LOAEL : 100 mg/kg

Application Route : Intraperitoneal

Exposure time : 14 Days

Target Organs : Kidney

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species : Rat

LOAEL : 0.25 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Application Route : Oral Exposure time : 98 w

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate

Species : Dog
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 12 w
Target Organs : Blood

Species : Baboon
NOAEL : 0.5 mg/kg
LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 52 w

Target Organs : Gastrointestinal tract, Blood Symptoms : constipation, Diarrhoea

Sodium hydroxymethanesulphinate:

Species : Rat

NOAEL : 600 mg/kg Application Route : Ingestion Exposure time : 90 Days

Method : OECD Test Guideline 408

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

oxytetracycline:

Ingestion : Symptoms: Gastrointestinal disturbance, tooth discoloration

Remarks: May cause birth defects.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Ingestion : Symptoms: Abdominal pain, Diarrhoea, constipation, heart-

burn, Ulceration, Dizziness, Headache, Breathing difficulties,

Rash

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

SECTION 12: Ecological information

12.1 Toxicity

Components:

2-Pyrrolidone:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 4,600 - 10,000 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 500 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): > 500 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 22.2 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 30 min

Method: OECD Test Guideline 209

oxytetracycline:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 110 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 621 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

EC50 (Daphnia magna (Water flea)): 669 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Anabaena): 0.032 mg/l

Exposure time: 72 h

NOEC (Anabaena): 0.0031 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10

Toxicity to microorganisms : EC50 : 17.9 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

NOEC: 0.2 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

10

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 166.6 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 80.1 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 71.9

ma/

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 49.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.32 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 10 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Sodium hydroxymethanesulphinate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 370 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50 : > 1,000 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

Exposure time: 4 h

Remarks: Based on data from similar materials

Toxicity to fish (Chronic tox-

icity)

NOEC: 13.5 mg/l Exposure time: 35 d

Species: Danio rerio (zebra fish) Method: OECD Test Guideline 210

Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 5.6 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

2-Pyrrolidone:

Biodegradability : Result: Readily biodegradable.

Remarks: Based on data from similar materials

Sodium hydroxymethanesulphinate:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 77 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

Components:

2-Pyrrolidone:

Partition coefficient: n- : log Pow: -0.71

octanol/water Method: OECD Test Guideline 107

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Partition coefficient: n- : log Pow: 4.51

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxytetracycline)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxytetracycline)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(oxytetracycline)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

N.O.S.

(oxytetracycline)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(oxytetracycline)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not. Not applicable

Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.11
 28.09.2024
 4164051-00017
 Date of first issue: 17.04.2019

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E1 ENVIRONMENTAL 100 t 200 t

HAZARDS

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H301 : Toxic if swallowed. H315 : Causes skin irritation.

H317 : May cause an allergic skin reaction.
H319 : Causes serious eye irritation.

H341 : Suspected of causing genetic defects. H360D : May damage the unborn child.

H360FD : May damage fertility. May damage the unborn child.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.11 28.09.2024 4164051-00017 Date of first issue: 17.04.2019

Eye Irrit. : Eye irritation

Muta. : Germ cell mutagenicity
Repr. : Reproductive toxicity

Skin Irrit. : Skin irritation
Skin Sens. : Skin sensitisation

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min : Occupational exposure limit value (15-minute reference period)

(STEL) od

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Oxytetracycline / Diclofenac Formulation

Version 4.11	Revision Date: 28.09.2024	SDS Number: 4164051-00017	Date of last issue: 06.04.2024 Date of first issue: 17.04.2019	
Eye Irr	rit. 2	H319	Calculation method	
Skin S	ens. 1	H317	Calculation method	
Repr.	1A	H360FD	Calculation method	
STOT	RE 2	H373	Calculation method	
Aquati	c Acute 1	H400	Calculation method	
Aquati	c Chronic 1	H410	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN